Payment overview · 2025
General Payments
$1,119.46
63 reported records · 20 companies
Healthcare provider profile · identity verified
Brian J Matherne, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · HOUMA, LA · NPI 1437118890
Verified facts
What the public records show
CMS Open Payments records show Brian J Matherne, M.D. received $1,119.46 in general payments during 2025 across 63 reported records.
AstraZeneca Pharmaceuticals LP accounted for 17.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 30 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Kerendia, Mounjaro, Ozempic, Rybelsus, Trelegy Ellipta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 125 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 439 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 112 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 439 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 280 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 148 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 302 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $196.39 | 17.5% | 10 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $154.76 | 13.8% | 8 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $154.32 | 13.8% | 10 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $107.38 | 9.6% | 6 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $77.72 | 6.9% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $77.50 | 6.9% | 5 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $60.90 | 5.4% | 3 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $56.34 | 5.0% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $29.45 | 2.6% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $24.70 | 2.2% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $22.50 | 2.0% | 1 | 2025 |
| TOLMAR, INC. | Unresolved — no canonical attribution shown | $20.45 | 1.8% | 1 | 2025 |
| SCILEX PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $20.00 | 1.8% | 1 | 2025 |
| Corium, LLC | Unresolved — no canonical attribution shown | $19.93 | 1.8% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.20 | 1.6% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $17.89 | 1.6% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $16.76 | 1.5% | 1 | 2025 |
| Optinose US, Inc. | Unresolved — no canonical attribution shown | $16.35 | 1.5% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $16.18 | 1.4% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $11.74 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,119.46 | 63 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $154.76 | 8 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $114.64 | 5 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $103.45 | 7 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $103.45 | 7 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $84.90 | 5 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $77.72 | 5 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $75.16 | 4 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $69.86 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $63.73 | 4 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $56.34 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $54.58 | 3 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $45.36 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $32.22 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $32.22 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $29.45 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $29.45 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $24.70 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE Normalized: freestyle libre |
Device | Abbott Laboratories | $22.50 | 1 | 2025 |
Source payment records
|
|||||
| JATENZO Normalized: jatenzo |
Drug | TOLMAR, INC. | $20.45 | 1 | 2025 |
Source payment records
|
|||||
| ZTLido Normalized: ztlido |
Drug | SCILEX PHARMACEUTICALS INC. | $20.00 | 1 | 2025 |
Source payment records
|
|||||
| Azstarys Normalized: azstarys |
Drug | Corium, LLC | $19.93 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $17.89 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $16.76 | 1 | 2025 |
Source payment records
|
|||||
| Xhance Normalized: xhance |
Drug | Optinose US, Inc. | $16.35 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $16.18 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $15.54 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $14.49 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $13.77 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $13.72 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $11.74 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 302 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 125 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 439 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 280 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 148 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 112 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
64 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
51 | 12 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
125 | 24 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
439 | 74 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
112 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
439 | 74 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
280 | 45 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
78 | 21 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
148 | 28 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
302 | 39 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1435 | 361 |
| Gabapentin | Gabapentin | 853 | 232 |
| Metformin Hcl | Metformin Hcl | 806 | 198 |
| Lisinopril | Lisinopril | 720 | 189 |
| Levothyroxine Sodium | Levothyroxine Sodium | 644 | 144 |
| Amlodipine Besylate | Amlodipine Besylate | 498 | 134 |
| Metoprolol Succinate | Metoprolol Succinate | 495 | 134 |
| Pantoprazole Sodium | Pantoprazole Sodium | 476 | 137 |
| Furosemide | Furosemide | 456 | 130 |
| Jardiance | Empagliflozin | 439 | 74 |
| Tamsulosin Hcl | Tamsulosin Hcl | 436 | 116 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 430 | 124 |
| Sertraline Hcl | Sertraline Hcl | 419 | 90 |
| Tramadol Hcl | Tramadol Hcl | 397 | 147 |
| Alprazolam | Alprazolam | 367 | 66 |
| Clonazepam | Clonazepam | 354 | 61 |
| Diclofenac Sodium | Diclofenac Sodium | 349 | 147 |
| Metoprolol Tartrate | Metoprolol Tartrate | 341 | 72 |
| Omeprazole | Omeprazole | 340 | 93 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 324 | 167 |
| Hydrochlorothiazide | Hydrochlorothiazide | 308 | 82 |
| Eliquis | Apixaban | 302 | 39 |
| Glipizide | Glipizide | 301 | 86 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 298 | 79 |
| Losartan Potassium | Losartan Potassium | 298 | 92 |
| Zolpidem Tartrate | Zolpidem Tartrate | 289 | 42 |
| Mounjaro | Tirzepatide | 280 | 45 |
| Allopurinol | Allopurinol | 268 | 76 |
| Trazodone Hcl | Trazodone Hcl | 260 | 52 |
| Clopidogrel | Clopidogrel Bisulfate | 251 | 60 |
| Pravastatin Sodium | Pravastatin Sodium | 246 | 55 |
| Meloxicam | Meloxicam | 228 | 89 |
| Duloxetine Hcl | Duloxetine Hcl | 222 | 46 |
| Escitalopram Oxalate | Escitalopram Oxalate | 222 | 52 |
| Prednisone | Prednisone | 222 | 184 |
| Montelukast Sodium | Montelukast Sodium | 215 | 76 |
| Simvastatin | Simvastatin | 211 | 53 |
| Quetiapine Fumarate | Quetiapine Fumarate | 202 | 36 |
| Potassium Chloride | Potassium Chloride | 200 | 39 |
| Pioglitazone Hcl | Pioglitazone Hcl | 197 | 52 |
| Tizanidine Hcl | Tizanidine Hcl | 193 | 62 |
| Atenolol | Atenolol | 191 | 41 |
| Temazepam | Temazepam | 191 | 41 |
| Meclizine Hcl | Meclizine Hcl | 166 | 62 |
| Gemfibrozil | Gemfibrozil | 159 | 45 |
| Carvedilol | Carvedilol | 158 | 42 |
| Fenofibrate | Fenofibrate | 158 | 39 |
| Alendronate Sodium | Alendronate Sodium | 150 | 37 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 148 | 46 |
| Ozempic | Semaglutide | 148 | 28 |
| Memantine Hcl | Memantine Hcl | 143 | 31 |
| Ondansetron Odt | Ondansetron | 143 | 57 |
| Finasteride | Finasteride | 139 | 32 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 138 | 104 |
| Ezetimibe | Ezetimibe | 133 | 40 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 128 | 60 |
| Carbinoxamine Maleate | Carbinoxamine Maleate | 126 | 87 |
| Farxiga | Dapagliflozin Propanediol | 125 | 24 |
| Pregabalin | Pregabalin | 112 | 32 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 112 | 20 |
| Buspirone Hcl | Buspirone Hcl | 106 | 26 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 104 | 38 |
| Glimepiride | Glimepiride | 103 | 26 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 101 | 26 |
| Fluoxetine Hcl | Fluoxetine Hcl | 100 | 24 |
| Nifedipine Er | Nifedipine | 100 | 21 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 95 | 24 |
| Estradiol | Estradiol | 91 | 23 |
| Paroxetine Hcl | Paroxetine Hcl | 90 | 24 |
| Doxycycline Hyclate | Doxycycline Hyclate | 84 | 61 |
| Bupropion Hcl Sr | Bupropion Hcl | 83 | 16 |
| Cephalexin | Cephalexin | 83 | 63 |
| Amitriptyline Hcl | Amitriptyline Hcl | 82 | 17 |
| Januvia | Sitagliptin Phosphate | 82 | 23 |
| Donepezil Hcl | Donepezil Hcl | 81 | 17 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 81 | 18 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 79 | 29 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 78 | 61 |
| Trulicity | Dulaglutide | 78 | 21 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 73 | 15 |
| Spironolactone | Spironolactone | 70 | 18 |
| Divalproex Sodium | Divalproex Sodium | 69 | suppressed |
| Celecoxib | Celecoxib | 68 | 22 |
| Citalopram Hbr | Citalopram Hydrobromide | 68 | 14 |
| Levetiracetam | Levetiracetam | 68 | suppressed |
| Amoxicillin | Amoxicillin | 66 | 52 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 65 | 40 |
| Linzess | Linaclotide | 64 | suppressed |
| Valsartan | Valsartan | 64 | 21 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 63 | 14 |
| Xarelto | Rivaroxaban | 63 | suppressed |
| Lovastatin | Lovastatin | 61 | 18 |
| Terbinafine Hcl | Terbinafine Hcl | 61 | 21 |
| Diclofenac Potassium | Diclofenac Potassium | 60 | 22 |
| Metformin Hcl Er | Metformin Hcl | 59 | 17 |
| Benazepril Hcl | Benazepril Hcl | 58 | 16 |
| Methocarbamol | Methocarbamol | 58 | 32 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 57 | 18 |
| Hydralazine Hcl | Hydralazine Hcl | 57 | 12 |
| Mupirocin | Mupirocin | 57 | 41 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 56 | suppressed |
| Ramipril | Ramipril | 54 | 16 |
| Aripiprazole | Aripiprazole | 51 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 51 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 51 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 51 | 23 |
| Synthroid | Levothyroxine Sodium | 51 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 50 | 12 |
| Clonidine Hcl | Clonidine Hcl | 49 | 15 |
| Fluconazole | Fluconazole | 49 | 37 |
| Fluticasone Propionate | Fluticasone Propionate | 49 | 22 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 49 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 49 | 12 |
| Megestrol Acetate | Megestrol Acetate | 48 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 48 | 12 |
| Azithromycin | Azithromycin | 47 | 45 |
| Bupropion Xl | Bupropion Hcl | 47 | 11 |
| Famotidine | Famotidine | 47 | 12 |
| Doxazosin Mesylate | Doxazosin Mesylate | 45 | 12 |
| Tresiba Flextouch U-100 | Insulin Degludec | 45 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 44 | 15 |
| Midodrine Hcl | Midodrine Hcl | 43 | suppressed |
| Irbesartan | Irbesartan | 41 | 12 |
| Etodolac | Etodolac | 40 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 39 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 39 | 34 |
| Ibuprofen | Ibuprofen | 37 | suppressed |
| Sucralfate | Sucralfate | 37 | 16 |
| Betamethasone Valerate | Betamethasone Valerate | 36 | 24 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 36 | 27 |
| Warfarin Sodium | Warfarin Sodium | 36 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 35 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 34 | suppressed |
| Lorazepam | Lorazepam | 33 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 33 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 33 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 33 | suppressed |
| Tradjenta | Linagliptin | 31 | suppressed |
| Baclofen | Baclofen | 29 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 29 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 28 | 25 |
| Imipramine Hcl | Imipramine Hcl | 28 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 28 | 18 |
| Valacyclovir | Valacyclovir Hcl | 28 | 20 |
| Lactulose | Lactulose | 27 | 17 |
| Nystatin | Nystatin | 27 | 20 |
| Primidone | Primidone | 26 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 26 | suppressed |
| Torsemide | Torsemide | 26 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Carbamazepine | Carbamazepine | 25 | suppressed |
| Colchicine | Colchicine | 25 | 14 |
| Fenofibrate | Fenofibrate Nanocrystallized | 25 | suppressed |
| Metronidazole | Metronidazole | 25 | 19 |
| Myrbetriq | Mirabegron | 25 | suppressed |
| Novolog Flexpen | Insulin Aspart | 25 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 24 | suppressed |
| Metoprolol-Hydrochlorothiazide | Metoprolol/Hydrochlorothiazide | 24 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 24 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 23 | 19 |
| Liothyronine Sodium | Liothyronine Sodium | 23 | suppressed |
| Naproxen | Naproxen | 23 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 23 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 23 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 23 | suppressed |
| Cilostazol | Cilostazol | 22 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 21 | suppressed |
| Dutasteride | Dutasteride | 21 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Bicalutamide | Bicalutamide | 20 | suppressed |
| Hydrocortisone | Hydrocortisone | 20 | 12 |
| Kerendia | Finerenone | 20 | suppressed |
| Rybelsus | Semaglutide | 20 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 20 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 19 | suppressed |
| Elmiron | Pentosan Polysulfate Sodium | 19 | suppressed |
| Mirtazapine | Mirtazapine | 19 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 19 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 19 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 19 | suppressed |
| Indomethacin | Indomethacin | 18 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 18 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 17 | suppressed |
| Lubiprostone | Lubiprostone | 17 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 17 | suppressed |
| Testosterone | Testosterone | 17 | suppressed |
| Topiramate | Topiramate | 17 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 16 | suppressed |
| Diazepam | Diazepam | 16 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 16 | suppressed |
| Levofloxacin | Levofloxacin | 16 | 12 |
| Acebutolol Hcl | Acebutolol Hcl | 15 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 15 | suppressed |
| Latanoprost | Latanoprost | 15 | suppressed |
| Loperamide | Loperamide Hcl | 15 | 11 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Cefdinir | Cefdinir | 14 | 13 |
| Clindamycin Hcl | Clindamycin Hcl | 14 | 11 |
| Divalproex Sodium Er | Divalproex Sodium | 14 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 14 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 14 | suppressed |
| Balsalazide Disodium | Balsalazide Disodium | 13 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 13 | suppressed |
| Chlordiazepoxide Hcl | Chlordiazepoxide Hcl | 13 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Eszopiclone | Eszopiclone | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Prempro | Estrogen,con/M-Progest Acet | 13 | suppressed |
| Repaglinide | Repaglinide | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Humulin R | Insulin Regular, Human | 12 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 12 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 12 | suppressed |
| Olanzapine | Olanzapine | 12 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 12 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 12 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 12 | suppressed |
| Vraylar | Cariprazine Hcl | 12 | suppressed |
| Bumetanide | Bumetanide | 11 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 11 | suppressed |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 11 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Nexletol | Bempedoic Acid | 11 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 11 | suppressed |
| Telmisartan | Telmisartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,119.46 · 63 records | AstraZeneca Pharmaceuticals LP | Auvelity, Azstarys, CAPVAXIVE, Cologuard Collection Kit, ELIQUIS, FARXIGA, FREESTYLE LIBRE, JARDIANCE, JATENZO, KISUNLA, Kerendia, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, QULIPTA, REPATHA, REXULTI, Rybelsus, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UBRELVY, VOQUEZNA, VRAYLAR, Wegovy, Xhance, ZAVZPRET, ZEPBOUND, ZORYVE, ZTLido | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error